Page 5,753«..1020..5,7525,7535,7545,755..5,7605,770..»

Autism after stem cell therapy – Video

Posted: Published on February 6th, 2013

Autism after stem cell therapy He is a known case of Autism with history of CIAB, but thereafter parents noticed delayed motor milestones in him along with delayed speech and hyperactivity. So at 2 years, he was diagnosed to have Autism and put on rehabilitation program including Occupational Therapy, Physiotherapy and speech therapy. Neurologically, he has near normal tone and reflexes. On examination, he has all sensation intact and no motor weakness. He has normal vision, hearing but bisyllable speech. He has social isolation. He has no bowel and bladder control and has bed wetting present. Functionally, he needs supervision in all ADL and wheel chair bound for mobility On FIM scores he scores 62 On ISAA he scores 130 Stem Cell Therapy done at NeuroGen Brain and Spine Institute Surana Sethia Hospital Sion-Trombay Rd, Suman Ngr Opp Corporate Park, Chembur, Mumbai -- 71. Tel : 022 - 25283706, 022 - 25281610, Mob : +91 9920 200 400 http://www.neurogen.in http://www.stemcellsmumbai.com By: neurogenbsi … Continue reading

Comments Off on Autism after stem cell therapy – Video

Stem Cell Therapy for Spinal Cord Injury – Video

Posted: Published on February 6th, 2013

Stem Cell Therapy for Spinal Cord Injury He is a paraplegic has history of fall from height in 1993, leading to fracture D4 and paraplegia with complete bowel bladder loss. He was managed conservatively and has been undergoing rehabilitation since then. Neurologically, he is hypertonic and hyperflexic. On examination: he has sensory loss below T4. He has grade 0 muscle power in bilateral lower extremity and near normal upper extremity. He has no bowel and bladder control and is on condom catheter. He has bilateral knee flexion contracture =10. On ASIA impairment scale he scores'A'. On investigation: MRI: 6/7/2012: Wedge compression of the D4 vertebral body with a focal area of scarring within the spinal canal involving the arachnoid and the spinal cord at D3-4 level. A large cord syrinx extending cranially upto C4vetebral level with a smaller syrinx extending caudally up to D7 vertebral level. EMG / SSEP: It is suggestive of a severe lesion affecting the posterior column conduction from both lower limbs. There is evidence of predominantly Upper motor neurone lesion affecting the lower limbs. Functionally, he needs assistance in most ADL and wheel chair bound for mobility. Stem Cell Therapy done at NeuroGen Brain … Continue reading

Comments Off on Stem Cell Therapy for Spinal Cord Injury – Video

What are the important issues when it comes to cartilage repair… Things you need to know! – Video

Posted: Published on February 6th, 2013

What are the important issues when it comes to cartilage repair... Things you need to know! http://www.stemcellsarthritistreatment.com The first is to know that whatever method is used is effective in building articular cartilage. There are two types of cartilage, hyaline cartilage which is the tough gristle that caps the ends of long bones and fibrocartilage which is the softer cartilage which is found in knee meniscus, and the labral tissue of the shoulder and hip. The second issue is what type of cell to use. Adult autologous mesenchymal stem cells are the ones that are easiest to harvest and to use. But are they the most effective? Allogeneic donor cells may prove to be a more viable source, providing graft versus host reactions will not be an issue. How do we ensure stem cell survival in the hostile environment of an arthritic joint? The use of growth factors and other "protective" factors need to be considered. What is the optimal condition that will ensure a good outcome? Much work has been done in the field of biomaterial scaffolding. Is it really necessary? While in vitro studies and small animal studies appear promising, no definitive human studies have been done. It … Continue reading

Comments Off on What are the important issues when it comes to cartilage repair… Things you need to know! – Video

Intracellular distribution of nontargeted quantum dots – Supplementary Video: 39658 – Video

Posted: Published on February 6th, 2013

Intracellular distribution of nontargeted quantum dots - Supplementary Video: 39658 Supplementary video of original research "Intracellular distribution of nontargeted quantum dots after natural uptake and microinjection" to be published in the open acesss International Journal of Nanomedicine by Damalakiene L, Bagdonas S, Karabanovas V, et al. Background: The purpose of this study was to elucidate the mechanism of natural uptake of nonfunctionalized quantum dots in comparison with microinjected quantum dots by focusing on their time-dependent accumulation and intracellular localization in different cell lines. Methods: The accumulation dynamics of nontargeted CdSe/ZnS carboxyl-coated quantum dots (emission peak 625 nm) was analyzed in NIH3T3, MCF-7, and HepG2 cells by applying the methods of confocal and steady-state fluorescence spectroscopy. Intracellular colocalization of the quantum dots was investigated by staining with Lysotracker. Results: The uptake of quantum dots into cells was dramatically reduced at a low temperature (4C), indicating that the process is energy-dependent. The uptake kinetics and imaging of intracellular localization of quantum dots revealed three accumulation stages of carboxyl-coated quantum dots at 37C, ie, a plateau stage, growth stage, and a saturation stage, which comprised four morphological phases: adherence to the cell membrane; formation of granulated clusters spread throughout the cytoplasm; localization of … Continue reading

Comments Off on Intracellular distribution of nontargeted quantum dots – Supplementary Video: 39658 – Video

Regen BioPharma Files IND Application With FDA On HemaXellerate I

Posted: Published on February 6th, 2013

By RTT News, February 05, 2013, 10:59:00 AM EDT (RTTNews.com) - Regen BioPharma, a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. (BMSN.PK), on Tuesday announced filing of an Investigational New Drug application with the FDA to initiate clinical trials assessing the company's HemaXellerate I stem cell drug in patients with drug-refractory aplastic anemia. HemaXellerate I is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies. If the clinical trial is successful, the company plans to expand use of HemaXellerate I to other conditions associated with bone marrow dysfunction, with the overall goal of entering the hematopoietic growth factor market, which is substantial in size and currently includes drugs such as Neupogen, Neulasta, Leukine and Revolade. The planned clinical trial anticipates recruiting 10 patients who have failed standard of care, which will be treated with HemaXellerate I and followed for safety parameters and signals of efficacy. Therapeutic effects will be quantified based on immunological measurements, as well as improvement in blood counts. Patients in the trial will be assessed for one year, however, because the trial is unblinded, data will be available as the … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on Regen BioPharma Files IND Application With FDA On HemaXellerate I

Trigger turns muscle stem cells into brown fat: Discovery identifies potential obesity treatment

Posted: Published on February 6th, 2013

Feb. 5, 2013 Ottawa scientists have discovered a trigger that turns muscle stem cells into brown fat, a form of good fat that could play a critical role in the fight against obesity. The findings from Dr. Michael Rudnicki's lab, based at the Ottawa Hospital Research Institute, were published today in the journal Cell Metabolism. "This discovery significantly advances our ability to harness this good fat in the battle against bad fat and all the associated health risks that come with being overweight and obese," says Dr. Rudnicki, a senior scientist and director for the Regenerative Medicine Program and Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute. He is also a Canada Research Chair in Molecular Genetics and professor in the Faculty of Medicine at the University of Ottawa. Globally, obesity is the fifth leading risk for death, with an estimated 2.8 million people dying every year from the effects of being overweight or obese, according to the World Health Organization. The Public Health Agency of Canada estimates that 25% of Canadian adults are obese. In 2007, Dr. Rudnicki led a team that was the first to prove the existence of adult skeletal muscle stem cells. … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Trigger turns muscle stem cells into brown fat: Discovery identifies potential obesity treatment

Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics

Posted: Published on February 6th, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (VSTM), a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the publication of data for VS-5584 in Molecular Cancer Therapeutics. VS-5584 is a potent and selective inhibitor of the PI3K/mTOR pathway. Previous research has described a central role of this pathway in cancer stem cells. The current study details the biochemical properties and preclinical effects of this compound in multiple human tumor models. The PI3K/mTOR signaling pathway appears critical for the survival and self-renewal of cancer stem cells, said Jonathan Pachter, Ph.D., Verastem Vice President and Head of Research. We have established a broad platform to assess cancer stem cell inhibition in multiple types of human cancer. VS-5584 has been one of the most impressive cancer stem cell inhibitors we have seen to date across these assays. VS-5584 demonstrated potent and highly selective activity against class 1 PI3K enzymes and dual-inhibitory actions against mTORC1 and mTORC2. The compound was profiled across >400 kinases covering all major families of the human kinome. In addition to the biochemical effects, VS-5584 exhibited broad anti-tumor efficacy, including tumor regression, across multiple human tumor models in the … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Scientific Data on PI3K/mTOR Inhibitor VS-5584 Published in Molecular Cancer Therapeutics

Fighting fat with fat: Muscle stem cells may hold key to battling obesity

Posted: Published on February 6th, 2013

CTVNews.ca Staff Published Tuesday, Feb. 5, 2013 12:06PM EST Last Updated Tuesday, Feb. 5, 2013 10:41PM EST Muscle stem cells can be made to produce a type of good fat in the body that helps burn energy, according to ground-breaking Canadian research that may one day lead to a treatment for obesity. Researchers at the Ottawa Hospital Research Institute are the first to discover that adult muscle stem cells not only produce muscle fibres, but can also turn into whats known as brown fat. Brown fat is a tissue that burns energy and is vital to the bodys ability to keep warm and regulate its temperature. Having more brown fat is associated with being leaner, the researchers say, which makes a potential new method for inducing the body to produce more an exciting discovery in the field of obesity research. It is the magic of stem cells, study co-author Dr. Hang Yin told CTV News. Stem cells have a lot of potential. In this case muscle stem cells, we can turn them into brown fat cells. Lead study author Dr. Michael Rudnicki and his team not only discovered that muscle stem cells can become brown fat, but also how. The … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Fighting fat with fat: Muscle stem cells may hold key to battling obesity

Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for …

Posted: Published on February 6th, 2013

SAN DIEGO, CA--(Marketwire - Feb 5, 2013) - Regen BioPharma a wholly-owned subsidiary of Bio-Matrix Scientific Group Inc. ( PINKSHEETS : BMSN ), announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I stem cell drug in patients with drug-refractory aplastic anemia. HemaXellerate I is a patient-specific composition of cells that have previously been demonstrated to repair damaged bone marrow and stimulate production of blood cells based on previous animal studies.The company, together with an internationally-renowned group of stem cell researchers, recently published the scientific basis for the HemaXellerate I product which may be found at http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf. "Currently patients with aplastic anemia who are resistant to drugs and ineligible for bone marrow transplant have no therapeutic options.We are fortunate to be in the position to have developed a novel approach to potentially treat this terrible condition," said David Koos, CEO of Bio-Matrix."To our knowledge the HemaXellerate I product is the only therapy that has potential to simultaneously block the underlying cause of aplastic anemia while at the same time rebuilding the bone marrow tissue that has been damaged by the disease." If the clinical trial is successful, the … Continue reading

Posted in Stem Cell Human Trials | Comments Off on Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I(TM) Stem Cell Drug for …

Stem cell discovery identifies potential obesity treatment

Posted: Published on February 6th, 2013

Nutrition and Fitness Health Home>>Nutrition and Fitness>>Health news Written by: QMI Agency Feb. 6, 2013 (SHUTTERSTOCK) Scientists at the Ottawa Hospital Research Institute say they have discovered a trigger that turns muscle stem cells into brown fat, a form of good fat that could play a critical role in the fight against obesity. "This discovery significantly advances our ability to harness this good fat in the battle against bad fat and all the associated health risks that come with being overweight and obese," Dr. Michael Rudnicki, a senior scientist at the Institute, said in a statement Tuesday. The research team say mice that were injected with an agent to reduce a gene regulator called miR-133 produced more brown fat, were protected from obesity and had an improved ability to process glucose. Did you find what you were looking for on our website? Please let us know. See original here: Stem cell discovery identifies potential obesity treatment … Continue reading

Comments Off on Stem cell discovery identifies potential obesity treatment

Page 5,753«..1020..5,7525,7535,7545,755..5,7605,770..»